Novo Nordisk launches a next generation of FlexPen®
- Details
- Category: Novo Nordisk
Novo Nordisk announced the launch of a next generation of FlexPen® at the European Association for the Study of Diabetes (EASD) Annual Meeting. The new insulin injection device builds upon the high standards set by the current version of FlexPen®, with new features providing improved safety, convenience and ease of use for people with diabetes.
Pfizer and Medivation Enter into Global Agreement to Co-Develop and Market Dimebon
- Details
- Category: Pfizer
Pfizer Inc (NYSE: PFE) and Medivation, Inc.(NASDAQ: MDVN) announced that they have entered into an agreement to develop and commercialize Dimebon, Medivation's investigational drug for treatment of Alzheimer's disease and Huntington's disease. Dimebon currently is being evaluated in an international, confirmatory Phase III trial in patients with mild-to-moderate Alzheimer's disease.
TRANSCEND® trial confirms long-term protective benefits and excellent tolerability profile
- Details
- Category: Boehringer Ingelheim
The results of the TRANSCEND® trial demonstrate that Micardis® 80mg (telmisartan) reduces the risk of cardiovascular death, myocardial infarction/heart attack and stroke in high-risk cardiovascular patients by 13% compared with those patients already receiving best standard of care (p=0.048), referring to the same endpoint as that defined as the primary endpoint of the landmark HOPE trial published in 2000.[1,2]
Anavex completes successful preclinical studies on lead Alzheimer's drug candidate
- Details
- Category: Clinical Trials
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL), a biopharmaceutical company engaged in the discovery and development of novel therapeutics to treat Central Nervous System (CNS) diseases and cancer, today announced the successful completion of preclinical studies (in-vitro and in-vivo in mice) on ANAVEX 2-73, a novel sigma-1 receptor agonist for the treatment of Alzheimer's disease.
Novartis decides not to pursue further development of Aurograb(TM)
- Details
- Category: Novartis
Novartis has decided not to pursue further development of the pharmaceuticals pipeline project Aurograb(TM), an add-on therapy to antibiotics that was being assessed for use in treating deep-seated staphylococcal infections, following a review of recent Phase II clinical data showing a lack of efficacy.
Rivaroxaban Phase II Data in ACS to be Presented at AHA Congress in November
- Details
- Category: Bayer
The development of Xarelto® (rivaroxaban), a novel oral anticoagulant, has taken another step forward. Phase II results in patients with acute coronary syndrome (ACS) have been chosen for the Late Breaking Clinical Trial session at the American Heart Association's (AHA) upcoming Annual Meeting in New Orleans, USA.
Abbott Fund to Build First Pediatric HIV/AIDS Clinic in Tanzania
- Details
- Category: Abbott
The Abbott Fund joined representatives from the U.S. government, Baylor College of Medicine, the government of Tanzania and other partners today at a U.S. President's Emergency Plan for AIDS Relief (PEPFAR) news conference to announce a joint effort to improve care and treatment for children with HIV/AIDS in Tanzania.
More Pharma News ...
- GlaxoSmithKline and Valeant Pharmaceuticals announce worldwide collaboration agreement
- Bristol-Myers Squibb and Pfizer Provide Update on Apixaban Clinical Development Program
- ADAGIO trial results show Azilect® slows progression of Parkinson's disease
- Brings complementary capabilities in India to address patient populations most at risk
- Alpharma Responds To Unsolicited Proposal By King Pharmaceuticals, Inc.
- King Proposes Acquisition of Alpharma for $33 Per Share in Cash
- New Trial to Evaluate Nexavar® as Adjuvant Therapy in Liver Cancer